The agreement covers RTI’s complete line of surgical specialties implants and is effective starting 1 January 2014 for a term of three years.

RTI is the only provider with a comprehensive biologic solutions portfolio for use in hernia repair. The portfolio includes Fortiva porcine dermis, Cortiva human dermis, Tutopatch bovine pericardium and Tutomesh fenestrated bovine pericardium.

The surgical specialties implants are sterilized through the patented Tutoplast tissue sterilization process, a validated chemical sterilization process that thoroughly penetrates tissue, removing antigenicity and inactivating pathogens. Terminal sterilization using low dose gamma irradiation achieves a sterility assurance level (SAL) of 10-6.

RTI Surgical president and CEO Brian K. Hutchison noted the company is pleased to announce this agreement with Yankee Alliance.

"We look forward to offering their members our complete portfolio of surgical specialties implants which are backed by our stellar safety record of more than five million implants sterilized with zero incidence of implant-associated infection," Hutchison added.